Search research articles
Contact Us
Filters
Showing results (101-110 of 126) with videos related to
Page
of 13
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
Robert D Morgan, George J Burghel, Nicola Flaum, et al.
BMC Cancer
|
April 2, 2021
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study
Reem D Mahmood, Danielle Shaw, Tine Descamps, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial
Alexander D Murphy, Catharine Porter, Ann White, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial
Alexander D Murphy, Catharine Porter, Ann White, et al.
The Lancet. Oncology
|
November 11, 2018
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
Ignace Vergote, Corneel Coens, Matthew Nankivell, et al.
Journal of Clinical Pathology
|
June 23, 2022
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Journal of the National Cancer Institute
|
October 3, 2002
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies
Gordon C Jayson, Jamal Zweit, Alan Jackson, et al.
BMC Cancer
|
October 25, 2024
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
Margherita Carucci, Andrew Clamp, Cong Zhou, et al.
British Journal of Cancer
|
November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Robert D Morgan, Xin Wang, Bethany M Barnes, et al.
Journal of the American Chemical Society
|
July 5, 2013
Small-molecule-induced clustering of heparan sulfate promotes cell adhesion
Naohiro Takemoto, Tetsuya Suehara, Heidie L Frisco, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 126) with videos related to
Sort By:
Page
of 13
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene
Robert D Morgan, George J Burghel, Nicola Flaum, et al.
BMC Cancer
|
April 2, 2021
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study
Reem D Mahmood, Danielle Shaw, Tine Descamps, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial
Alexander D Murphy, Catharine Porter, Ann White, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial
Alexander D Murphy, Catharine Porter, Ann White, et al.
The Lancet. Oncology
|
November 11, 2018
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
Ignace Vergote, Corneel Coens, Matthew Nankivell, et al.
Journal of Clinical Pathology
|
June 23, 2022
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
Robert D Morgan, George J Burghel, Nicola Flaum, et al.
Journal of the National Cancer Institute
|
October 3, 2002
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies
Gordon C Jayson, Jamal Zweit, Alan Jackson, et al.
BMC Cancer
|
October 25, 2024
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors
Margherita Carucci, Andrew Clamp, Cong Zhou, et al.
British Journal of Cancer
|
November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer
Robert D Morgan, Xin Wang, Bethany M Barnes, et al.
Journal of the American Chemical Society
|
July 5, 2013
Small-molecule-induced clustering of heparan sulfate promotes cell adhesion
Naohiro Takemoto, Tetsuya Suehara, Heidie L Frisco, et al.
Page
of 13